- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02086604
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University, James Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Relapsed or refractory de novo or transformed DLBCL disease following at least one prior systemic therapy (for DLBCL).
- CD30 immunohistochemical staining using the anti-CD30 BerH2 antibody must be available on the most recent biopsy specimen. During dose escalation, patients can be either CD30 positive or CD30 negative. During dose expansion, 15 patients must be CD30 positive and 15 patients must be CD30 negative.
- Post-ASCT or not a candidate for ASCT. Prior allogeneic stem cell transplant is allowed if patient is off all immunosuppressives and has no evidence of active GVHD.
- Prior treatment with brentuximab vedotin is allowed provided the patient did not progress on BV or within 30 days of last dose of BV. Patients must be at least 3 months from the last dose of BV.
- Bidimensional measurable disease of at least 1.5 cm in the greatest transverse diameter as documented by CT or PET/CT.
- At least 18 years of age.
- ECOG performance status ≤ 2
Bone marrow and organ function as defined below:
- Absolute neutrophil count (ANC) ≥ 1,000/mcl
- Platelets ≥ 50,000/mcl
- Serum bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) OR serum bilirubin ≤ 3.0 x IULN for patients with Gilbert's disease or documented hepatic involvement with NHL
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x IULN OR ALT and AST ≤ 5.0 x IULN for patients with documented hepatic involvement with NHL
- Creatinine clearance ≥ 60 mL/min/1.73 m2 as calculated by Cockcroft-Gault
- Women of childbearing potential must follow pregnancy testing requirements as outlined in the Revlimid REMS® program material. This is defined as either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of contraception (one highly effective method and one additional effective method AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last doses of brentuximab vedotin and lenalidomide. Women of childbearing potential must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a woman of childbearing potential even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- All study participants must be registered into the mandatory Revlimid REMS® program and be willing to comply with its requirements. Per standard Revlimid REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS® program.
- Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Primary mediastinal B-cell lymphoma
- A history of other primary invasive malignancy that has not been in remission for at least 3 years or a current diagnosis of myelodysplastic syndrome (MDS) or an immature leukemia such as acute myeloid leukemia (AML).
- Known active cerebral/meningeal lymphoma.
- Present or history of progressive multifocal leukoencephalopathy (PML).
- NYHA Class III or IV congestive heart failure.
- Active CTCAE version 4.03 grade 3 or higher viral, bacterial, or fungal infection.
- Known to be positive for hepatitis B by surface antigen expression and hepatitis B core antibody.
- Known to have active hepatitis C infection (positive by polymerase chain reaction) or on antiviral therapy for hepatitis C within 6 months prior to the first doses of brentuximab vedotin and lenalidomide.
- Known to be positive for HIV.
- Receiving chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed at least 3 weeks prior to study entry, unless underlying disease is progressing on therapy.
- Currently receiving any other investigational agents.
- Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or lenalidomide.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours of starting lenalidomide.
- Receiving immunosuppressive therapy.
- Refractory to prior therapy with brentuximab vedotin (evidence of progression within 30 days of the last dose).
- Prior therapy with lenalidomide.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Starting Dose (brentuximab vedotin & lenalidomide)
Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle. Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle. |
Other Names:
Other Names:
|
Experimental: Dose Level 1 (brentuximab vedotin & lenalidomide)
Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle. Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle. |
Other Names:
Other Names:
|
Experimental: Dose Level 2 (brentuximab vedotin & lenalidomide)
Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle. Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle. |
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by grade and frequency of adverse events
Time Frame: 30 days after completion of treatment
|
Adverse events will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
|
30 days after completion of treatment
|
Maximum Tolerated Dose (MTD) as measured by the number of dose-limiting toxicities in each dose level (cohort)
Time Frame: Completion of the first cycle for all participants in dose expansion phase (approximately 12 months)
|
MTD is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle.
Dose escalations will proceed until the MTD has been reached.
|
Completion of the first cycle for all participants in dose expansion phase (approximately 12 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate as measured by CD30 expression
Time Frame: Up to 2 years after discontinuation of treatment
|
The objective response rate by CD30 expression (proportion of positive cells, staining intensity, or both) is defined as the proportion of patients with CR or PR stratified by different values or categories of CD30 expression.
Positive CD30 expression is defined as ≥1% staining of the malignant cells.
|
Up to 2 years after discontinuation of treatment
|
Overall response rate
Time Frame: Up to 2 years after discontinuation of treatment
|
Complete response rate (CR) + Partial response rate (PR) = Overall response rate according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
|
Up to 2 years after discontinuation of treatment
|
Duration of response
Time Frame: Up to 2 years after discontinuation of treatment
|
Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (including radiographic and clinical progression) or to death due to any cause, whichever comes first. Duration of response data will be censored on the day following the date of the last disease assessment documenting absence of progressive disease for patients who do not have tumor progression and are still on study at the time of an analysis, are given antitumor treatment (including stem cell transplant) other than the study treatment, or are removed from study prior to documentation of tumor progression. Duration of response will only be calculated for the subgroup of patients achieving a CR or PR. |
Up to 2 years after discontinuation of treatment
|
Progression-free survival (PFS)
Time Frame: Up to 2 years after discontinuation of treatment
|
PFS is defined as the time from start of study treatment to first documentation of tumor progression (including radiographic and clinical progression) or to death due to any cause, whichever comes first. PFS data will be censored on the day following the date of the last disease assessment documenting absence of progressive disease for patients who do not have tumor progression and are still on study at the time of an analysis, are given antitumor treatment (including stem cell transplant) other than the study treatment, or are removed from study prior to documentation of tumor progression. Patients lacking an evaluation of tumor response after their first dose will have their event time censored at 1 day. |
Up to 2 years after discontinuation of treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nancy Bartlett, M.D., Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Brentuximab Vedotin
Other Study ID Numbers
- 201404056
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Large B-Cell, Diffuse
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
NeoImmuneTechRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell LymphomaUnited States
Clinical Trials on Brentuximab vedotin
-
University Hospital, CaenRecruiting
-
Washington University School of MedicineSeagen Inc.CompletedMyelodysplastic Syndromes | Leukemia, Acute Myeloid | Leukemia, Lymphoblastic,AcuteUnited States
-
Seagen Inc.TerminatedSystemic Lupus ErythematosusUnited States
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, France
-
Seagen Inc.Millennium Pharmaceuticals, Inc.No longer availableLymphoma, Non-Hodgkin | Lymphoma, T-Cell, Cutaneous | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, United Kingdom, Belgium, Serbia, Australia, Bulgaria, France, Germany, Hungary, Italy, Poland, Romania, Russian Federation, Spain, Switzerland
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
Samsung Medical CenterMillennium Pharmaceuticals, Inc.CompletedNon-Hodgkin LymphomaKorea, Republic of
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, Germany
-
TG Therapeutics, Inc.CompletedHodgkin's LymphomaUnited States
-
Fondazione Italiana Linfomi ONLUSCompletedRelapsed/Refractory Hodgkin's LymphomaItaly